Table 4.
Visual analogue scale scores, quality-of-life variables, and morphine-equivalent doses
|
Number included in analysis |
Median number of timepoints used to generate summary score |
Summary score |
Difference in means* | p value | |||||
|---|---|---|---|---|---|---|---|---|---|
| Immediate radiotherapy | Deferred radiotherapy | Immediate radiotherapy | Deferred radiotherapy | Immediate radiotherapy | Deferred radiotherapy | ||||
| Summary visual analogue scale score | |||||||||
| On average how much chest pain have you felt today? | 93 | 96 | 10 (6 to 12) | 10 (5 to 12) | 12·0 (3·3 to 23·3) | 9·0 (2·9 to 27·0) | 0·6 (−3·3 to 4·6) | 0·75 | |
| On average how much has chest pain bothered you today? | 93 | 96 | 10 (6 to 12) | 10 (5 to 12) | 9·1 (2·7 to 20·6) | 7·8 (2·6 to 24·1) | 0·8 (−3·1 to 4·6) | 0·70 | |
| On average how much pain have you felt today from the site of your previous chest wall procedure? | 93 | 95 | 10 (6 to 12) | 10 (5 to 12) | 6·9 (2·4 to 16·4) | 5·3 (2·2 to 16·8) | 1·0 (−2·3 to 4·2) | 0·56 | |
| On average how much has pain from the site of your previous chest wall procedure bothered you today? | 93 | 95 | 10 (6 to 12) | 10 (5 to 12) | 5·5 (1·2 to 15·1) | 5·5 (2·1 to 17·7) | 0·5 (−2·7 to 3·6) | 0·76 | |
| QLQ-C30 summary score | |||||||||
| Global health status | 91 | 92 | 5 (3 to 6) | 5 (3 to 6) | 59·6 (45·8 to 70·8) | 61·6 (43·1 to 74·9) | −1·2 (−5·2 to 2·8) | 0·55 | |
| Physical functioning | 91 | 92 | 5 (3 to 6) | 5 (3 to 6) | 71·0 (54·8 to 83·7) | 70·3 (49·5 to 84·4) | −0·1 (−3·1 to 2·9) | 0·94 | |
| Pain | 91 | 93 | 5 (3 to 6) | 5 (3 to 6) | 22·8 (8·7 to 35·1) | 16·7 (6·7 to 35·9) | 1·3 (−3·1 to 5·6) | 0·57 | |
| EQ-5D summary score (time trade-off scores) | 94 | 95 | 5 (3 to 6) | 5 (3 to 6) | 0·72 (0·56 to 0·83) | 0·72 (0·58 to 0·82) | −0·02 (−0·06 to 0·02) | 0·38 | |
| Mean change in QLQ-C30 scores from randomisation to 1 month | |||||||||
| Global health status | 83 | 87 | NA | NA | 6·2 (21·0) | 5·3 (24·3) | 0·8 (−5·5 to 7·0) | 0·81 | |
| Physical functioning | 83 | 88 | NA | NA | 5·7 (12·6) | 4·5 (12·7) | 0·9 (2·8 to −4·7) | 0·62 | |
| Fatigue | 83 | 88 | NA | NA | −3·2 (23·1) | −2·6 (20·8) | 0·0 (−5·5 to 5·5) | 1·00 | |
| Pain | 84 | 88 | NA | NA | −0·6 (22·2) | −3·2 (23·0) | 2·8 (−3·3 to 9·0) | 0·36 | |
| Appetite loss | 83 | 88 | NA | NA | 2·0 (30·1) | −2·7 (32·1) | 1·9 (−5·5 to 9·2) | 0·62 | |
| Morphine-equivalent dose summary score | 102 | 101 | 5 (4 to 6) | 5 (4 to 6) | 2·7 (0 to 17·3) | 1·9 (0 to 10·5) | NA† | 0·50 | |
Data are n, median (IQR), or mean (SD). QLQ-C30=European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire—Core 30. EQ-5D=EuroQoL-5D. NA=not applicable.
*
Adjusted difference in mean summary scores (immediate radiotherapy group – deferred radiotherapy group).
†
Non-parametric comparison was used because of skewed data, so no difference in means was generated.